Aaron Wealth Advisors LLC Has $686,000 Holdings in GSK plc (NYSE:GSK)

Aaron Wealth Advisors LLC trimmed its holdings in GSK plc (NYSE:GSK) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,286 shares of the pharmaceutical company’s stock after selling 425 shares during the period. Aaron Wealth Advisors LLC’s holdings in GSK were worth $686,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Eastern Bank acquired a new position in GSK in the 3rd quarter valued at $26,000. ST Germain D J Co. Inc. raised its stake in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares in the last quarter. Sunbelt Securities Inc. lifted its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners grew its stake in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new position in GSK in the 3rd quarter valued at about $42,000. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GSK has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 0.0 %

GSK opened at $33.46 on Monday. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The company has a fifty day moving average of $34.02 and a 200-day moving average of $37.98. The stock has a market cap of $69.34 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.